Arvinas Inc (NASDAQ:ARVN) major shareholder Ventures Iii L.P. 5Am sold 361,129 shares of the business’s stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $14.16, for a total transaction of $5,113,586.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Shares of Arvinas stock traded up $0.07 during trading on Wednesday, reaching $22.70. The company had a trading volume of 102,000 shares, compared to its average volume of 115,484. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.52 and a current ratio of 8.52. Arvinas Inc has a fifty-two week low of $10.19 and a fifty-two week high of $25.61. The firm has a market cap of $738.33 million and a PE ratio of -0.89.
Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Tuesday, March 26th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.08. The business had revenue of $3.44 million for the quarter, compared to the consensus estimate of $3.38 million. On average, equities analysts predict that Arvinas Inc will post -2.09 earnings per share for the current year.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Arvinas from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. Evercore ISI assumed coverage on shares of Arvinas in a research note on Thursday, April 11th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. Arvinas presently has an average rating of “Hold” and a consensus price target of $20.33.
Arvinas Company Profile
Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer.
See Also: Ex-Dividend
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.